Vanguard Global Advisers
DMAC icon

Vanguard Global Advisers’s DiaMedica Therapeutics DMAC Stock Holding History

Vanguard Global Advisers’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.6K Hold
12,301
– – ﹤0.01% 2835
2026
Q1 		$83.3K Buy
+12,301
New +$97.5K ﹤0.01% 2803

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Global Advisers's DMAC Position: Q2 2026 in Review

Vanguard Global Advisers held its DiaMedica Therapeutics (DMAC) position steady in Q2 2026 at 12,301 shares worth $86.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2835.

Vanguard Global Advisers first reported a position in DMAC in Q1 2026 and has held it in 2 quarters since. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Vanguard Global Advisers held 12,301 shares of DiaMedica Therapeutics worth $86.6K as of Q2 2026.
  • Vanguard Global Advisers left its DiaMedica Therapeutics share count unchanged in Q2 2026.
  • DiaMedica Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2835 holding.
  • Vanguard Global Advisers first reported a position in DiaMedica Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.